Shire has picked up a stake in Chronos as part of a deal that sees it transfer CNS programs in return for milestones and an opportunity to buy back the drugs.

Cambridge, MA-based startup Amylyx Pharmaceuticals has been given charity backing to run its first in-human clinical trial for its oral combination ALS…

Zafgen fell about 40% in after-hours trading on news that it has suspended development of its lead obesity candidate beloranib, which had been on a clinical…

Newly unveiled Oncorus has raised a $57 million Series A to back its efforts to use next-gen oncolytic viruses to treat aggressive cancers including a type of…

Third Rock-backed Jounce Therapeutics has done its first major deal with Celgene that could be worth up to $2.6 billion.

Third Rock Ventures is launching Fulcrum Therapeutics, which works to control gene expression via small molecules, with a Series A round of $55 million.

Buried deep down in Novartis’ Q2 results out this morning was a previously unknown rejection by the FDA for a copycat version of Amgen’s blockbuster drug…

Bayer has partnered with micro-cap diagnostics player T2 Biosystems as part of its R&D efforts in blood coagulation.